The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant’s controlling stockholder – in connection with Immunovant’s January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day’s closing price.

If you are currently an Immunovant investor and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-immunovant-investigation-imvt.html

You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.

THE COMPANY: Immunovant is a clinical-stage immunology company. In December 2019, a blank check company under the name Health Sciences Acquisitions Corporation (“HSAC”) merged with Immunovant Sciences Ltd., which was a majority-owned subsidiary of Roivant. Subsequent to the merger, HSAC changed its name to Immunovant, Inc. At all times since the merger, Roivant has controlled a majority of Immunovant’s stock, holding between 54.6% and 73.8% of Immunovant’s shares.

THE TRANSACTION: On January 13, 2025, Immunovant announced, prior to the start of trading, that it had entered into a share purchase agreement with Roivant. Pursuant to the agreement, Immunovant sold 16,845,010 shares of the company’s common stock to Roivant via a private placement for $20.00 per share, a $3.48 per share discount to the prior trading day’s closing price. The last time Immunovant’s share price had closed as low as $20.00 per share was in August 2023 – nearly a year and a half before the private placement. This $3.48 per share discount, when multiplied by the 16,845,010 shares Roivant received pursuant to the agreement, equates to a benefit to Roivant of nearly $60 million at the expense of Immunovant and its shareholders.

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in merger and securities fraud cases. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-corporate-takeover.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Contacts

Robbins Geller Rudman & Dowd LLP

J.C. Sanchez, Jennifer N. Caringal

655 W. Broadway, Suite 1900, San Diego, CA 92101

800-449-4900

info@rgrdlaw.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.